Artivion, Inc. (NYSE:AORT) Given Average Recommendation of “Moderate Buy” by Brokerages

Artivion, Inc. (NYSE:AORT) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $49.1143.

A number of analysts have recently weighed in on the stock. Citigroup reissued an “outperform” rating on shares of Artivion in a research report on Friday, October 10th. Canaccord Genuity Group reissued a “buy” rating and set a $51.00 price objective on shares of Artivion in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, January 21st. Citizens Jmp lifted their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Finally, Wall Street Zen lowered Artivion from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 24th.

Insiders Place Their Bets

In other Artivion news, Director Elizabeth A. Hoff sold 4,200 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $45.10, for a total transaction of $189,420.00. Following the completion of the sale, the director owned 27,189 shares in the company, valued at $1,226,223.90. The trade was a 13.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Amy Horton sold 4,572 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $44.42, for a total transaction of $203,088.24. Following the completion of the transaction, the chief accounting officer owned 130,058 shares in the company, valued at approximately $5,777,176.36. The trade was a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 234,511 shares of company stock worth $10,612,452. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Artivion

A number of large investors have recently bought and sold shares of AORT. Champlain Investment Partners LLC bought a new position in shares of Artivion during the third quarter valued at approximately $17,912,000. Two Sigma Investments LP boosted its position in Artivion by 235.5% during the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock valued at $18,906,000 after purchasing an additional 313,446 shares during the period. Vanguard Group Inc. grew its stake in Artivion by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after buying an additional 232,424 shares during the last quarter. Voloridge Investment Management LLC increased its position in Artivion by 442.9% in the third quarter. Voloridge Investment Management LLC now owns 220,076 shares of the company’s stock worth $9,318,000 after buying an additional 179,541 shares during the period. Finally, Invesco Ltd. increased its position in Artivion by 40.8% in the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after buying an additional 139,370 shares during the period. Institutional investors own 86.37% of the company’s stock.

Artivion Price Performance

Shares of AORT stock opened at $39.49 on Friday. The firm has a fifty day simple moving average of $44.34 and a 200-day simple moving average of $42.44. The company has a market capitalization of $1.87 billion, a PE ratio of -164.52 and a beta of 1.59. Artivion has a twelve month low of $21.97 and a twelve month high of $48.25. The company has a current ratio of 3.93, a quick ratio of 2.88 and a debt-to-equity ratio of 0.50.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The company’s quarterly revenue was up 18.9% compared to the same quarter last year. Equities research analysts anticipate that Artivion will post 0.37 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.